Chipscreen's NW001 Injection Trial Application for Advanced Malignancies Accepted by NMPA
On August 5, 2026, Chipscreen Biosciences announced it received an acceptance notice from the National Medical Products Administration's Center for Drug Evaluation for its clinical trial application of NW001 injection, co-developed with Chengdu Weixin Xinyu Biotechnology. The drug targets advanced malignant tumors, including solid tumors and lymphomas. Acceptance moves the review process to a new stage; CDE will oversee subsequent progress and trial arrangements per regulations.
On August 5, 2026, Chipscreen Biosciences announced that it recently received the Acceptance Notice for Registration Clinical Trial of Domestically Produced Drugs issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The clinical trial application for NW001 injection, co-developed with Chengdu Weixin Xinyu Biotechnology Co. , Ltd. , for the treatment of advanced malignant tumors (solid tumors and lymphomas) has been accepted.
The acceptance of this clinical trial application marks a new stage in the review process for NW001 injection. This drug, developed jointly by the company and its partner, is intended for the treatment of advanced solid tumors and lymphomas. Subsequent review progress and specific arrangements for clinical trials will be advanced by the CDE in accordance with relevant regulations.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 40/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.